Evaluating off-label uses of anticancer drugs: Time for a change

Annals of Internal Medicine

Volumn 150, Issue 5, 2009, Pages 353-354

  Sox, Harold C ^a  

^a AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; PRESCRIPTION DRUG;

BIOTECHNOLOGICAL PRODUCTION; CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG LEGISLATION; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE QUALITY; HEALTH INSURANCE; OFF LABEL DRUG USE; POLICY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; BOOK; ECONOMICS; MEDICAL LITERATURE; MEDICARE; STANDARDS; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG LABELING; MEDICARE; PHARMACOPOEIAS AS TOPIC; PRESCRIPTION DRUGS; REFERENCE BOOKS, MEDICAL; UNITED STATES;

EID: 61449179296     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-5-200903030-00110     Document Type: Editorial

References (8)

1. Henney JE. Safeguarding patient welfare: who's in charge? [Editorial]. Ann Intern Med. 2006;145:305-7. [PMID: 16908923]
2. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]
3. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D; U.S. Preventive Services Task Force. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med. 2007;147:871-5. [PMID: 18087058]
4. Eden J, Wheatley B, McNeil B, Sox H, eds. Knowing What Works In Health Care. A Roadmap for the Nation. Washington, DC: National Academies Pr; 2008.
5. Tillman K, Burton B, Jacques LB, Phurrough SE. Compendia and anticancer therapy under Medicare. Ann Intern Med. 2009;150:348-50.
6. Abernethy AP, Raman G, Balk EM, Hammond JM, Orlando LA, Wheeler JL, et al. Systematic review: reliability of compendia methods for off-label oncology indications. Ann Intern Med. 2009;150:336-43.
7. Gillick MR. Controlling off-label medication use. Ann Intern Med. 2009;150:344-7.
8. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Aff (Millwood). 2006;25:1218-30. [PMID: 16966717]